rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
10
|
pubmed:dateCreated |
2006-11-19
|
pubmed:abstractText |
We aimed to evaluate the efficacy, advantage, and safety of a 24-week regimen with high-dose interferon-alpha (INF-alpha; 6 million units thrice weekly) plus ribavirin (1000-1200 mg/day) combination therapy for 46 Taiwanese chronic hepatitis C (CHC) patients with persistently normal or near-normal alanine aminotransferase (PNALT) levels.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1478-3223
|
pubmed:author |
pubmed-author:ChangWen-YuWY,
pubmed-author:ChenShinn-CherngSC,
pubmed-author:ChuangWan-LongWL,
pubmed-author:DaiChia-YenCY,
pubmed-author:HouNei-JenNJ,
pubmed-author:HsiehMing-YenMY,
pubmed-author:HsiehMing-YuhMY,
pubmed-author:HuangJee-FuJF,
pubmed-author:LeeLi-PoLP,
pubmed-author:LinZu-YauZY,
pubmed-author:WangLiang-YenLY,
pubmed-author:YuMing-LungML
|
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1187-95
|
pubmed:meshHeading |
pubmed-meshheading:17105583-Adult,
pubmed-meshheading:17105583-Aged,
pubmed-meshheading:17105583-Alanine Transaminase,
pubmed-meshheading:17105583-Antiviral Agents,
pubmed-meshheading:17105583-Case-Control Studies,
pubmed-meshheading:17105583-Female,
pubmed-meshheading:17105583-Hepatitis C, Chronic,
pubmed-meshheading:17105583-Humans,
pubmed-meshheading:17105583-Interferon-alpha,
pubmed-meshheading:17105583-Male,
pubmed-meshheading:17105583-Middle Aged,
pubmed-meshheading:17105583-Ribavirin
|
pubmed:year |
2006
|
pubmed:articleTitle |
A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
|
pubmed:affiliation |
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|